Life Science Investors
We can help de-risk decision making on potential investments increasing the likelihood of success. We specialise in due-diligence of new biomedical technology. We provide transparent summaries of the technologies, indicating strengths and weaknesses in the evidence. Importantly your decision will be evidence based and unbiased.
We can help pharma in multiple areas of decision making. We can perform literature reviews for new areas of interest, identify evidence gaps and aid in the assessment of new pre-clinical models or markers.
Combining systematic review with expertise in biomedical science we are uniquely placed to help inform reviews or evaluations with a deeper understanding of the underlying science. These skills are essential with the movement toward precision medicine.
We have a long background in academia and our aims are to improve scientific reporting, improve reproducbility, support open science and improve clinical translation. We can provide expertise in evidence based decision making, systematic review and cancer cell science. We are uniquely placed in these two research fields. We are very interested in continuing to collaborate with any academic partners.